Jake Seliger has died
News of writer and long-time Hacker News contributor Jake Seliger’s death from aggressive tongue cancer prompted an outpouring of tributes to his candid blogging about illness, mortality, and the medical system. Commenters reflect on the brutality of cancer, the value and limits of aggressive treatment and clinical trials, and broader ethical questions around FDA regulation, patient autonomy, and experimental drugs. Many also note how his writing helped others process suffering and inspired calls to continue his advocacy for reforms that could give future patients more options and agency.
Confirmation and Immediate Reactions
- Death was confirmed via family updates on a fundraising page and on his blog.
- Some early confusion over timing and sources was quickly resolved by direct statements from relatives.
- Many express shock at how fast things progressed from the hospice post to his death and emphasize relief that his suffering is over.
- Condolences to his wife, infant daughter, and extended family are widespread.
Who Jake Was and Why HN Cares
- Several ask who he is and why there is a site-wide black bar.
- Others explain he was a long‑time HN participant with very high karma, an active blogger, novelist, and researcher, whose detailed writing about his cancer journey had been heavily discussed on HN.
- Some note that “black bar criteria” are informal and community-/moderator-driven; being a long‑time, widely read community member is considered sufficient.
Writing, Agency, and Over‑/Under‑Treatment
- His blog chronicled the diagnosis, treatment choices (including surgeries, radiation, and missed opportunities for early chemo), and later reflections on regret and overtreatment.
- A much‑praised essay argues that extreme “agentic” pursuit of every possible treatment can itself be harmful, especially under uncertainty.
- Commenters highlight how unusually candid, analytic, and emotionally direct his and his wife’s writing was.
Debate on FDA Regulation and Experimental Access
- One major thread debates whether terminal patients should have broader access to experimental drugs.
- Pro‑access side: terminal patients should be free to choose; current rules are over‑cautious, cost lives, and are shaped by institutional self‑protection.
- Skeptical side: regulations were “written in blood”; loosening rules risks exploitation, unsafe treatments, erosion of trust in medicine, and biased trials.
- Sub‑debates cover supplements vs. drugs, fraud vs. informed consent, clinical trial ethics, and the tension between utilitarian calculus and political reality.
Reflections on Cancer, Suffering, and Death
- Many share personal cancer stories (parents, siblings, their own diagnoses), contrasting rapid vs. drawn‑out deaths and the trade‑off between time to prepare and prolonged suffering.
- Themes include the meaning of suffering, human adaptation to chronic pain, and how people often display unexpected strength once “there is no choice.”
Digital Legacy and Memorialization
- Discussion touches on what happens to accounts after death and how to plan digital legacies, with links to checklists and guides.
- Some note the value his HN comments and blog may have for his daughter in the future.
- A side discussion considers moderating hostile blog comments on end‑of‑life posts.
Family Participation and Ongoing Advocacy
- Family members participate, thanking the community and describing how much the online response meant.
- His wife commits to continuing advocacy for FDA and clinical‑trial reform and invites collaboration.